BSRT MPH - RadNet VP Affairs
| RDNT Stock | USD 46.54 0.62 1.35% |
Insider
BSRT MPH is VP Affairs of RadNet Inc
| Address | 1510 Cotner Avenue, Los Angeles, CA, United States, 90025 |
| Phone | 310 478 7808 |
| Web | https://www.radnet.com |
RadNet Management Efficiency
The company has return on total asset (ROA) of 0.0235 % which means that it generated a profit of $0.0235 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0399 %, meaning that it created $0.0399 on every $100 dollars invested by stockholders. RadNet's management efficiency ratios could be used to measure how well RadNet manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0 in 2025. Return On Capital Employed is likely to gain to 0.04 in 2025. At this time, RadNet's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 3.5 B in 2025, whereas Non Current Liabilities Other is likely to drop slightly above 3.6 M in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| Lehmann JD | Sotera Health Co | 56 | |
| Nicole Lambert | Myriad Genetics | 50 | |
| Ryan Douglas | Exagen Inc | N/A | |
| Steven Graves | Sera Prognostics | N/A | |
| Pamela Wong | Myriad Genetics | 56 | |
| Jeffrey Bojar | Biodesix | N/A | |
| Paul Changelian | Aclaris Therapeutics | N/A | |
| Xavier MS | bioAffinity Technologies Warran | 55 | |
| James Loerop | Aclaris Therapeutics | 60 | |
| MD Frcp | Aclaris Therapeutics | 63 | |
| Michael Biehl | Sotera Health Co | 68 | |
| Sally Turner | Sotera Health Co | N/A | |
| Matt Stauffer | Biodesix | N/A | |
| Kevin Haas | Myriad Genetics | 39 | |
| Joseph Monahan | Aclaris Therapeutics | 68 | |
| Ian Anderson | Aclaris Therapeutics | N/A | |
| Kristin Gibbs | Sotera Health Co | N/A | |
| Robert Harrison | Sera Prognostics | 59 | |
| Nadia Altomare | Sera Prognostics | 53 | |
| Jinxiang Li | Burning Rock Biotech | 39 | |
| Ryan Siurek | Biodesix | 52 | |
Management Performance
| Return On Equity | 0.0399 | ||||
| Return On Asset | 0.0235 |
RadNet Inc Leadership Team
Elected by the shareholders, the RadNet's board of directors comprises two types of representatives: RadNet inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RadNet. The board's role is to monitor RadNet's management team and ensure that shareholders' interests are well served. RadNet's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RadNet's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mital Patel, Executive Vice President - Finance | ||
| Christine Gordon, Senior California | ||
| Ranjan Jayanathan, Chief VP | ||
| Norman Hames, COO of Western Operations, Executive VP, Secretary and Director | ||
| Michael Murdock, Executive Acquisitions | ||
| Howard MD, President Chairman | ||
| Stephen Forthuber, COO of Eastern Operations and Executive VP | ||
| Ruth VilligerWilson, HR Director | ||
| Gregory MD, Chief VP | ||
| BSRT MPH, VP Affairs | ||
| David Katz, Chief VP | ||
| Mark Stolper, CFO and Executive VP | ||
| Derek Bomar, Senior Management |
RadNet Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is RadNet a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0399 | ||||
| Return On Asset | 0.0235 | ||||
| Profit Margin | 0 % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | 4.43 B | ||||
| Shares Outstanding | 74.04 M | ||||
| Shares Owned By Insiders | 10.40 % | ||||
| Shares Owned By Institutions | 88.75 % | ||||
| Number Of Shares Shorted | 6.03 M | ||||
| Price To Earning | 55.56 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for RadNet Stock Analysis
When running RadNet's price analysis, check to measure RadNet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RadNet is operating at the current time. Most of RadNet's value examination focuses on studying past and present price action to predict the probability of RadNet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RadNet's price. Additionally, you may evaluate how the addition of RadNet to your portfolios can decrease your overall portfolio volatility.